eyeforpharma Barcelona 2016 conference

eyeforpharma 15 - 17 March 2016, Barcelona, Spain.
eyeforpharma Barcelona will set the vision for your 2020 plans. With 120% attendee growth you can join 1000+ industry leaders in commercial excellence, patient engagement and innovation at the unmissable pharma-stakeholder summit. As your customer takes charge this meeting will enable you take the steps you need to become their partner of choice.

The conference will bring together all key stakeholders, so you can collaborate and identify solutions in order to:

  • Gain Real Customer Insight. Reinvent your understanding of customer experience with a holistic multichannel solution
  • Deliver Outcomes. Enhance patient experience by partnering with external stakeholders and facilitating internal cross functionality
  • Sell Value. Engage the busier, more informed customer with impactful face-to-face, remote and digital communication
  • Develop a New Corporate Culture. Pioneer a progressive internal mind-set promoting collaboration, communication and trust

Why Attend?
90+ industry leading speakers including C-Suite, VP and Director level experts to share their experiences so you can make healthier corporate decisions. 2016 speakers include:

Keynotes

  • David Epstein, Novartis, Division Head and CEO Pharmaceuticals
  • Dominique Limet, ViiV, Healthcare
  • Jane Griffiths, Janssen, Company Group Chairman, Europe, Middle East & Africa
  • Gitte Aabo, LEO Pharma, CEO
  • Eduardo Javier Sanchiz Yrazu, Almirall, CEO
  • Murray Stewart, GSK, Chief Medical Officer
  • Tim Kneen, Merck, Executive President, Europe & Canada
  • David Loew, Sanofi Pasteur, COO
  • Andrew Hotchkiss, Eli Lilly and Company, President Europe and Canada
  • Jason DeGoes, Teva, SVP Patient Solutions

Patient Experience

  • Kasper Jerlang, LEO Pharma, Head - Global Patient Communications
  • Sanja Njegic, Novartis, Director Patient Relations, Europe
  • Henrik Finnern, Boehringer Ingelheim, Chief Patient Office
  • Anne Beal, Sanofi, Chief Patient Officer
  • Paul Robinson, MSD, Executive Director Scientific Medical and Patient Perspective

Commercial Excellence

  • Andreas Wandelt, Pfizer, Vice President, Global Sales and Marketing Services
  • Heléna Bargiel, LEO Pharma, Head of Global Field Force Excellence
  • Etienne Tichit, Novo Nordisk, Vice President, Commercial Excellence
  • Bharat Tewarie, UCB, EVP & Chief Marketing Officer
  • Chris-Carol Bremer, Grunenthal, SVP & Head of Marketing

See the complete speaker line-up here.

Don't miss Barcelona 2016, Europe’s premier pharmaceutical summit in commercial excellence, patient engagement and innovation!

Save €100 using World Pharma News unique code wpn100

For further information, please visit:
http://www.eyeforpharma.com/barcelona/

About eyeforpharma
Our mission is to make pharma more open and valued. The ultimate driver for the pharmaceutical industry's health is meeting the needs of patients, otherwise it will cease to matter. For healthcare to be as good as it could be, the strength, skills and resources of our industry need to be fully integrated into health outcomes and we need pharma experience at the decision-making table. We believe the industry must focus on a business model combining service with product, with patients at the center.

Most Popular Now

The Merck Accelerator Program 2019

The Merck Accelerator is looking for real partners so that you can work together in shaping the future. With programs in the headquarters in Germany, in China and the Sat...

Pre-clinical success for a universal flu vaccine o…

Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Co...

Imfinzi is the first immunotherapy to demonstrate …

AstraZeneca and MedImmune, its global biologics research and development arm, have presented data on overall survival (OS) in the Phase III PACIFIC trial of Imfinzi durin...

Global survey reveals that physicians need more in…

Results from a new global survey revealed that more than one-third (36%) of the 310 physicians surveyed do not think they have sufficient information required to make inf...

In clinical trials, new antibody therapy controls …

Thanks to improvements in antiretroviral therapy, HIV is now a manageable condition. Yet even the best drugs do not entirely eliminate the virus, which latently lingers i...

Sandoz Healthcare Access Challenge #SandozHACk ret…

Sandoz, the Novartis generics and biosimilars division, today announces the launch of the second Sandoz Healthcare Access Challenge (HACk). The #SandozHACk is a global co...

The Nobel Prize in Physiology or Medicine 2018 was…

Cancer kills millions of people every year and is one of humanity's greatest health challenges. By stimulating the inherent ability of our immune system to attack tumor c...

Novartis licenses three novel anti-infective progr…

Novartis announced today that it has entered into a licensing and equity agreement with Boston Pharmaceuticals for the development of three novel anti-infective drug cand...

Pfizer to award more than $3 million in grants to …

Pfizer Inc. today announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards. Four grants tota...

FDA approves first treatment for advanced form of …

The U.S. Food and Drug Administration today approved Libtayo (cemiplimab-rwlc) injection for intravenous use for the treatment of patients with metastatic cutaneous squam...

DNA islands effective as 'anti-bacterial drones'

Genomic "islands" that evolved from viruses can be converted into "drones" that disable Staphylococcus aureus, bacteria that are often resistant to antibiotics and pose a...

FDA awards 12 grants to fund new clinical trials t…

The U.S. Food and Drug Administration today announced that it has awarded 12 new clinical trial research grants totaling more than $18 million over the next four years to...